Novartis AG received FDA approval on March 28, 2025, for its therapy Pluvicto® for use in prostate cancer patients, increasing the eligible population threefold due to its new indication before chemotherapy; this treatment has shown a 59% reduction in disease progression. The approval highlights the importance of advanced therapeutics in prolonging lives for patients with metastatic castration-resistant prostate cancer.